Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TSHA-102 by Astellas Pharma for Rett Syndrome: Likelihood of Approval
TSHA-102 is under clinical development by Astellas Pharma and currently in Phase II for Rett Syndrome. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Taysha Gene Therapies's TSHA-102?
TSHA-102 is a gene therapy commercialized by Taysha Gene Therapies, with a leading Phase II program in Rett Syndrome. According...
Risk adjusted net present value: What is the current valuation of Taysha Gene Therapies's TSHA-102?
TSHA-102 is a gene therapy commercialized by Taysha Gene Therapies, with a leading Phase II program in Rett Syndrome. According...